TaiMed Biologics Inc. (TPEX:4147)
Taiwan · Delayed Price · Currency is TWD 80.50
-0.10 (-0.12%)
Sep 4, 2025, 1:30 PM CST
TaiMed Biologics Revenue
TaiMed Biologics had revenue of 137.54M TWD in the quarter ending June 30, 2025, a decrease of -6.40%. This brings the company's revenue in the last twelve months to 598.06M, down -6.79% year-over-year. In the year 2024, TaiMed Biologics had annual revenue of 610.16M with 24.07% growth.
Revenue (ttm)
598.06M
Revenue Growth
-6.79%
P/S Ratio
36.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
22.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 610.16M | 118.39M | 24.07% |
| Dec 31, 2023 | 491.78M | -71.23M | -12.65% |
| Dec 31, 2022 | 563.01M | 149.57M | 36.18% |
| Dec 31, 2021 | 413.44M | -309.04M | -42.78% |
| Dec 31, 2020 | 722.49M | 17.98M | 2.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 87.67M |
| Center Laboratories | 1.60B |